The FDA is reminding health care providers that tests to detect rupture of the amniotic membranes should not be used without other clinical assessments to make critical patient management decisions.
Risks Associated with Use of Rupture of Membranes Tests – Letter to Health Care Providers
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Takes Steps to Increase Availability of COVID-19 Vaccine
- Coronavirus (COVID-19) Update: June 11, 2021
- Viona Pharmaceuticals Inc., Issues Voluntary Nationwide Recall of Metformin HCl Extended-Release Tablets, USP 750 mg, Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
- Innova Medical Group Recalls Unauthorized SARS-CoV-2 Antigen Rapid Qualitative Test with Risk of False Test Results